IL3 Stock Overview
Manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Integra LifeSciences Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$41.60 |
| 52 Week Low | US$21.20 |
| Beta | 1.17 |
| 11 Month Change | -4.93% |
| 3 Month Change | -12.90% |
| 1 Year Change | -28.19% |
| 33 Year Change | -53.85% |
| 5 Year Change | -43.98% |
| Change since IPO | 283.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| IL3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.9% | 0.5% | -0.1% |
| 1Y | -28.2% | 0.9% | 2.4% |
Return vs Industry: IL3 underperformed the German Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: IL3 underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| IL3 volatility | |
|---|---|
| IL3 Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: IL3 has not had significant price volatility in the past 3 months.
Volatility Over Time: IL3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 3,946 | Jan De Witte | www.integralife.com |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Integra LifeSciences Holdings Corporation Fundamentals Summary
| IL3 fundamental statistics | |
|---|---|
| Market cap | €2.13b |
| Earnings (TTM) | €37.55m |
| Revenue (TTM) | €1.43b |
56.7x
P/E Ratio1.5x
P/S RatioIs IL3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IL3 income statement (TTM) | |
|---|---|
| Revenue | US$1.53b |
| Cost of Revenue | US$600.76m |
| Gross Profit | US$928.84m |
| Other Expenses | US$888.60m |
| Earnings | US$40.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.51 |
| Gross Margin | 60.72% |
| Net Profit Margin | 2.63% |
| Debt/Equity Ratio | 116.3% |
How did IL3 perform over the long term?
See historical performance and comparison